FDAsafety guidance77% confidence
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Alembic Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA202306. Sponsor: PLATINUM. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METFORMIN HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Neurology · Multiple Sclerosis
- Sub-indication
- General
Related signal: FDA Approves Fingolimod Hydrochloride Application by Alembic